While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value

Rezaie, Razie; Falakian, Zeinab; Mazloomzadeh, Saeideh; Ayati, Mohsen; Morakabati, Arman; Teimouri Dastjerdan, Mohammad Reza; Zare, Mohammad; Moghimi, Minoosh; Shahani, Tina; Biglari, Alireza

doi:10.29252/ibj.24.4.229

While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value

Authors

Razie Rezaie ¹

Zeinab Falakian ¹

Saeideh Mazloomzadeh ²

Mohsen Ayati ³

Arman Morakabati ⁴

Mohammad Reza Teimouri Dastjerdan ⁵

Mohammad Zare ⁶

Minoosh Moghimi ⁷

Tina Shahani ¹

Alireza Biglari ¹

¹ Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan 45139-56111, Iran

² Department of Epidemiology and Statistics, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan 45139-56111, Iran

³ Uro-Oncology Research Center, Tehran University of Medical Sciences (TUMS), Tehran 1419733141, Iran

⁴ Molecular Pathology Department of Mehr General Hospital, Tehran 1415755411, Iran

⁵ Urology Department of Farabi General Hospital, Mashhad 9178686918, Iran

⁶ Molecular Pathology Department of 17-Shahrivar General Hospital, Mashhad 91746, Iran

⁷ Department of Hemathology Onchology, Zanjan University of Medical Sciences (ZUMS), Zanjan 45139-56111, Iran

10.29252/ibj.24.4.229

Abstract

Background: Numerous studies confirmed that significant decrease in tissue decorin (DCN) expression is associated to tumor progression and metastasis in certain types of cancer including prostate cancer (PC). However, the potential prognostic value of tissue DCN in PC has not yet been investigated. Methods: A total number of 40 PC and 42 patients with benign prostatic hyperplasia (BPH) were investigated for the expression levels of DCN in their prostatic tissues using real-time quantitative polymerase chain reaction and immunohistochemical analyses. Urinary and plasma DCN levels were also measured by ELISA. Results: Despite no significant changes in the mean of urine and plasma DCN concentrations between the two study groups, tissue DCN mRNA was found to be 5.5fold lower in cancer than BPH (p = 0.0001). Similarly, the stained DCN levels appeared significantly lower in cancer patients with higher Gleason Scores (8 and 9, n = 6) than those with lower Gleason Scores (6 and 7, n = 26), with a p value of 0.049. Conclusion: Here, we report, for the first time, that urine and plasma DCN does not seem to have a diagnostic value in PC, while tissue DCN could potentially be used as a prognostic marker in PC.

Keywords

Benign prostatic hyperplasia

ELISA

Immunohistochemistry

Proteoglycans

Real-time qPCR